Abstract
IntroductionOur aim was to compare the effectiveness of second-line therapies in primary biliary cholangitis (PBC), with regards Obeticholic acid (OCA) and non-licensed therapy (fibric acid derivatives; FA) across a nationwide...
Highlights
Our aim was to compare the effectiveness of second-line therapies in primary biliary cholangitis (PBC), with regards Obeticholic acid (OCA) and non-licensed therapy across a nationwide cohort of patients
Abstracts experiencing a hospital admission with decompensated liver disease (11% vs 50%, p
Following an acute variceal bleed in cirrhotic patients, carvedilol is associated with survival benefit and fewer hospital admissions
Summary
Our aim was to compare the effectiveness of second-line therapies in primary biliary cholangitis (PBC), with regards Obeticholic acid (OCA) and non-licensed therapy (fibric acid derivatives; FA) across a nationwide cohort of patients (pts).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
